Eli Lilly and Company (NYSE:LLY) Shares Up 3.9% – Still a Buy?

Eli Lilly and Company (NYSE:LLY) shot up 3.9% during mid-day trading on Wednesday . The company traded as high as $976.68 and last traded at $955.4470. 6,165,708 shares were traded during mid-day trading, an increase of 91% from the average session volume of 3,220,580 shares. The stock had previously closed at $919.77.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA approval and commercial launch for Foundayo expands Lilly’s obesity franchise, offers low out‑of‑pocket pricing and broad accessibility (launch Apr. 6) — a clear growth catalyst for revenue and market share. Lilly’s weight-loss pill wins US approval (Reuters)
• Positive Sentiment: Bank of America reiterated a Buy and sees Foundayo as a preferred oral GLP‑1 that could expand the obesity market without heavily cannibalizing existing products — supports bullish analyst views and raised price targets. Bank of America sees Eli Lilly’s Foundayo as preferred oral GLP-1 (Yahoo Finance)
• Positive Sentiment: Unusually high call‑option volume signals elevated short‑term bullish positioning from traders, which can amplify upside on any favorable news or early uptake metrics. Eli Lilly and Company Target of Unusually High Options Trading (AmericanBankingNews)
• Neutral Sentiment: Acquisition of Centessa Pharmaceuticals (~$7.8B) diversifies Lilly into neuroscience and sleep‑wake treatments — positive for long‑term pipeline resilience but adds near‑term execution and integration risk. Eli Lilly to Acquire Centessa (InsiderMonkey)
• Negative Sentiment: Rival Novo Nordisk published a cross‑trial comparison claiming its oral Wegovy pill delivers greater weight loss and fewer side effects than Foundayo — a direct competitive narrative that can pressure expectations for Foundayo’s uptake and margins. Novo Nordisk Wegovy Data Challenges Foundayo (Yahoo Finance)
• Negative Sentiment: Broader political/regulatory risks — including reports of proposed tariffs on branded drugs and debate over codifying drug‑pricing deals — raise longer‑term margin and policy uncertainty for big pharma. That macro/regulatory backdrop has weighed on healthcare names despite product wins. Trump Administration Unveils Up to 100% Tariff on Branded Drugs (WSJ)

Wall Street Analyst Weigh In

Several research firms have recently weighed in on LLY. Leerink Partners lifted their price objective on Eli Lilly and Company from $1,234.00 to $1,296.00 and gave the stock an “outperform” rating in a research report on Thursday, February 5th. The Goldman Sachs Group set a $1,260.00 target price on Eli Lilly and Company in a report on Thursday, February 5th. Guggenheim dropped their price target on Eli Lilly and Company from $1,168.00 to $1,163.00 and set a “buy” rating on the stock in a research note on Monday. Freedom Capital raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, February 10th. Finally, Wells Fargo & Company lifted their price objective on shares of Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,222.22.

Eli Lilly and Company Stock Down 2.0%

The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. The stock has a 50 day simple moving average of $996.24 and a 200 day simple moving average of $966.65. The stock has a market cap of $884.21 billion, a price-to-earnings ratio of 40.78, a PEG ratio of 1.11 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The company had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. During the same period in the prior year, the firm earned $5.32 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in LLY. Maryland Capital Advisors Inc. bought a new stake in Eli Lilly and Company during the 4th quarter worth approximately $25,000. Osbon Capital Management LLC bought a new position in shares of Eli Lilly and Company in the fourth quarter valued at approximately $25,000. Vermillion & White Wealth Management Group LLC lifted its holdings in shares of Eli Lilly and Company by 84.2% in the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock valued at $27,000 after purchasing an additional 16 shares in the last quarter. Evolution Wealth Management Inc. purchased a new position in shares of Eli Lilly and Company during the second quarter valued at approximately $29,000. Finally, Steph & Co. grew its holdings in Eli Lilly and Company by 290.0% during the third quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after buying an additional 29 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.